A Study to Evaluate the Efficacy and Safety of HLX10 in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

• Status: Not yet recruiting
• Trial end date: 2026-06-30
• Target enrollment: 0
• Participant gender: All

Summary

This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of HLX10 + chemotherapy+ concurrent radiotherapy vs chemotherapy+ concurrent radiotherapy in subjects with Limited-Stage Small Cell Lung Cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Henlius Biotech
• Treatments: Carboplatin; Etoposide

Criteria

Inclusion Criteria:

1. Male or female, aged ≥18 years when signing the ICF.

2. Histologically or cytologically diagnosed with SCLC.

3. Diagnosed with LS-SCLC (stage Ⅰ-Ⅲ of the AJCC 8th edition of the cancer staging), which can be safely treated with curative radiation doses.

4. Major organs are functioning well.

Exclusion Criteria:

1. Histologically or cytologically confirmed mixed SCLC.

2. Subjects suitable for surgery. Subjects who are suitable for surgery but refuse surgical treatment can be included.

3. Patients who have previously received systematic anti-tumor treatments for small cell lung cancer, including but not limited to radiotherapy, chemotherapy, and immunotherapy.

4. Patients with other active malignancies within 5 years or at the same time.

5. Subjects with known history of severe allergy to any monoclonal antibody.

6. Subjects with known anaphylaxis to carboplatin/cisplatin or etoposide.

7. In the judgment of the investigator, subjects who have any other factors that may lead to a premature discontinuation.